AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06746090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Group A(Intervention): Patients who will be reminded daily via whatsapp text message.~Group B(Intervention): Patients who will be asked through a weekly phone call about elastic wear and then motivated.
Study NCT06629792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Cleanser
Description: The cleanser was instructed to be used twice daily over the course of 12 weeks
Study NCT06629792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer
Description: The Moisturizer was instructed to be applied to the global face twice daily over the course of 12 weeks.
Study NCT06629792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sunscreen SPF 30
Description: The Sunscreen was instructed to be applied once daily in the morning, with re-application with extended sun exposure per FDA guidelines over the course of 12 weeks.
Study NCT06094296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT06094296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT06094296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT06094296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT06094296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days
Study NCT05357365 — intervention group
Intervention type: OTHER
Intervention: questionnaire survey
Description: Questionnaire survey about occupational, mental, physical factors on one's health.
Study NCT06404671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed interval cytoreductive surgery (DICS)
Description: patients will receive six courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by delayed interval cytoreductive surgery (DICS) within 6 weeks of the last cycle of chemotherapy. After DICS, patients will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks.
Study NCT06404671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early interval cytoreductive surgery (EICS)
Description: patients will receive three courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by early interval cytoreductive surgery (EICS) within 6 weeks of the last cycle of chemotherapy. After EICS, patients will receive adjuvant three courses of intravenous carboplatin and paclitaxel every 3 weeks, then will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks.
Study NCT05531383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.
Study NCT06557187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
Description: hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost
Study NCT05408455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMST150 (Expiratory muscle training)
Description: Respiratory exercise device (Expiratory muscle trainer) developed for the expiratory muscles, and resistant expiratory muscle training were applied. Threshold loading was applied to the cases at approximately 30% of the respiratory muscle strength values measured in the 1st week. In respiratory muscle training, the pressure value was increased according to the tolerance of the patient and training was given at a pressure value between 50-75%. The subjects were asked to do 10 vigorous expirations at the adjusted pressure value by doing normal inspiration for expiratory muscle training in a comfortable sitting position. This program was applied in 3 sets in the same way for approximately 30 minutes. It was continued 3 days a week for 8 weeks
Study NCT05408455 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham EMST150 (Expiratory muscle training)
Description: The subjects were asked to perform normal inspiration and then exhale 10 times for expiratory muscle training without threshold loading. This program was applied in 3 sets in the same way for approximately 30 minutes. It will continue 3 days a week for 8 weeks
Study NCT06631456 — intervention group
Intervention type: OTHER
Intervention: PRP injection
Description: A total of 3 doses of intra-articular PRP were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
Study NCT06631456 — intervention group
Intervention type: OTHER
Intervention: Ozone therapy
Description: A total of 3 doses of intra-articular ozone therapy were applied to the symptomatic knees of the patients under ultrasound guidance, once a week.
Study NCT04791124 — intervention group
Intervention type: OTHER
Intervention: Electroencephalography
Description: EEG evaluation Composed by three consecutive tests~1. Resting state EEG, with either eyes open or closed~2. Auditory steady-state response (ASSR)~3. Auditory evoked potential
Study NCT06746376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Description:~Participants assigned to the intervention group will undergo a 8-week supervised hand exercise program designed to improve pain, manual dexterity, and functionality.
Study NCT06746831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-(+)-methamphetamine
Description: 15 mg
Study NCT06746831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-methamphetamine
Description: 15 mg
Study NCT06746831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1:1 racemic mixture of two isomers
Description: 15 mg R-Meth + 15 mg S-Meth
Study NCT06745973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-003
Description: Intravenous (IV) infusion.
Study NCT06746610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genetic Screening for Monogenic Diabetes
Description: This intervention involves genetic testing for monogenic diabetes (MDM) in recruited participants. The testing includes either a panel test specifically targeting genes associated with monogenic diabetes or whole exome sequencing (WES) to comprehensively identify genetic variants linked to MDM.~Precise diagnosis and treatmen：~1. The clinical trial of individualized treatment was carried out for the individuals with diabetes with HNF1A mutation.~2. The research team will closely follow up individuals with GCK mutation diabetes after suspending the current hypoglycemic drugs, and evaluate their clinical glucose metabolism related indicators.~3. Observe the dosage of sulfonylurea drugs used in individuals with different disease course and pancreatic function, and observe the impact of disease course and pancreatic function on the success rate of oral drug replacement.
Study NCT04789044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-001
Description: • PEG fusion is the application of a polyethylene glycol (PEG) using a combination of sequenced reagents to a freshly performed nerve coaptation, or neurorrhaphy, to allow the axonal membranes of the proximal and distal axonal stumps to fuse back together and re-establish full axonal continuity.
Study NCT06190886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-912
Description: Investigation Product Monotherapy
Study NCT05702853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: 500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
Study NCT06356519 — intervention group
Intervention type: DRUG
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
Study NCT04852770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial-Based Cognitive Therapy
Description: TBCT is an approach that includes psychoeducation and cognitive restructuring techniques concerning automatic thoughts, underlying assumptions and core beliefs related to the traumatic events. It is conducted in a therapeutic setting that makes use of experiential techniques, allowing the patient to refer to him/herself in the third person and thus taking distance from him or herself. One of TBCT techniques for dealing with guilt and shame, emotions that provoke great limitation to patients with PTSD, is the participation grid (PG). Another important technique is the consensual role-play (CRP), designed to help patients resolve ambivalence and make decisions. In addition, the most important TBCT technique, the Trial, was developed to help patients change dysfunctional negative core beliefs. Therapists who will conduct this approach have a specialization level in CBT. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
Study NCT04852770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Health Promotion
Description: The MBHP protocol is a structured program developed over 8 sessions, in group, where participants (8-15 people) meet every week for 2 hours (standard duration of one session), to experience the concepts and techniques of mindfulness. Participants are also given suggestions of daily activities to be implemented at home or in the workplace, that last in average 15-20 minutes, but may last up to 45 minutes in the case of more motivated and compliant participants. They are also encouraged to incorporate the idea of Mindfulness in their daily lives (the so-called informal practice), so that all daily activities somehow become opportunities to practice Mindfulness. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
Study NCT04852770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive psychotherapy
Description: PPT is the clinical and therapeutic work derived from PP. PPT consists of 15 specific practices that have been empirically validated, either separately, or in conjunction with two or three practices. After empirical validation, these practices were organized in a cohesive protocol of 15 sessions called PPT. Many of these practices have been studied through online interventions. In the present study, the protocol will be reduced to 14 sessions, with sessions called positive relationships, positive communication, and practical wisdom removed. It was understood that the other 12 would be more easily adapted to the moment of the study. (DUCKWORTH; STEEN; SELIGMAN, 2005; MONGRAIN; ANSELMO-MATTHEWS, 2012; RASHID; SELIGMAN, 2019). In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
Study NCT05929131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discharge instructions with pamphlet
Description: Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
Study NCT05929131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discharge instructions with video
Description: Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
Study NCT05929131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: verbal discharge instructions only
Description: Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
Study NCT06026709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EmoEase
Description: The online interventionEmoEase integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program.
Study NCT05536076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercapnia treatment
Description: Intermittent hypercapnia treatment five days per week for two weeks.
Study NCT05536076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypercapnia treatment
Description: Intermittent hypercapnia treatment five days per week for two weeks.
Study NCT05702853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Injection
Description: 30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
Study NCT06450262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
Description: 1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
Study NCT06450262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synjardy® 12.5mg/1000mg film-coated tablets
Description: 1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
Study NCT04875663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
Study NCT05335681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WARM SHOWER APPLICATION
Description: Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
Study NCT05788094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)
Description: * Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.
Study NCT05788094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine plus Tafenoquine (450 mg adult dose)
Description: * Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.
Study NCT05788094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
Description: * Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.
Study NCT06680024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal tube
Description: Intercostal tube drainage as a first management of second stage empyema
Study NCT05962736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The patients received a total of 24 sessions of treatment for 8 weeks, 3 sessions a week, starting from the postoperative 1st day after thorakaotomy. Each treatment session lasts between 60 and 90 minutes.
Study NCT05670184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
Study NCT05670184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
Study NCT04657991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafenib
Study NCT04657991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib
Study NCT04855799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aquamin
Description: Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
Study NCT05656040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
Study NCT06680024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video assisted thoracoscope
Description: Video assisted thoracoscopic surgery as a first management for second stage empyema
Study NCT06681480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: figure-of-eight active rTMS coil device
Description: rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains with a total of 15000 pulses during 5 weekdays at low frequency 0,5Hz Device: figure-of-eight active rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil, optic navigation system
Study NCT05656040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered subcutaneously
Study NCT05064085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Participants will be given Cemiplimab 350 mg IV day 1 every 21 days
Study NCT05064085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.
Study NCT04205786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12, orally, 2500 mcg, daily, for 90 days
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pain Inventory - Short Form survey
Description: Brief Pain Inventory - Short Form survey
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory - Short Form survey
Description: Brief Pain Inventory - Short Form survey
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FACT-ES Trial Outcome Index (Version 4)
Description: FACT-ES Trial Outcome Index (Version 4)
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-ES Trial Outcome Index (Version 4)
Description: FACT-ES Trial Outcome Index (Version 4)
Study NCT04205786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire to Assess Adherence to Aromatase Inhibitors
Description: Questionnaire to Assess Adherence to Aromatase Inhibitors